# BTC

Source: https://onco.cc/targets/btc/  
OnCo record `btc` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BTC (Probetacellulin) is a gene. In the public catalogues the evidence so far is association rather than a proven role.

## Summary

Growth factor that binds to EGFR, ERBB4 and other EGF receptor family members. Potent mitogen for retinal pigment epithelial cells and vascular smooth muscle cells.

Open Targets scores its association with cancer at 0.65 (direct and indirect evidence; datatypes literature 0.48, affected pathway 0.95, genetic association 0.35).

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: betacellulin; Probetacellulin
- Tags: cancer-genes-wave
- Symbol: BTC
- Class: other
- Biology: Growth factor that binds to EGFR, ERBB4 and other EGF receptor family members. Potent mitogen for retinal pigment epithelial cells and vascular smooth muscle cells. Location: Secreted, extracellular space; Cell membrane (UniProt). Locus 4q13.3 (HGNC).

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: none stated by the sources. Evidence tier "association-only" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:1121: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1121
- UniProt P35070: https://www.uniprot.org/uniprotkb/P35070/entry
- NCBI Gene 685: https://www.ncbi.nlm.nih.gov/gene/685
- Ensembl ENSG00000174808: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000174808

## Connected records

- collections: [Open Targets Platform](https://onco.cc/collections/open-targets/)
- trials: [A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]](https://onco.cc/trials/nct07111546/), [A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)](https://onco.cc/trials/nct07229625/), [HERIZON-BTC-302](https://onco.cc/trials/herizon-btc-302/), [Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC](https://onco.cc/trials/nct03478488/)

---
JSON: https://onco.cc/api/v1/entities/btc.json